5 Key Takeaways

• 1

  Preventive percutaneous coronary intervention may reduce major adverse cardiovascular events in high-risk atherosclerotic plaque patients.

• 2

  The PREVENT trial involved 1,606 patients assigned to receive either preventive percutaneous coronary intervention or medical therapy alone.

• 3

  After 2 years, patients receiving percutaneous coronary intervention had an 89% lower risk of the composite primary endpoint.

• 4

  Only 0.4% of patients in the intervention group experienced the composite primary endpoint compared to 3.4% in the medical therapy group.

• 5

  Findings persisted after a median follow-up of 4.4 years, indicating sustained benefits of percutaneous coronary intervention.